SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Drugs that provide the splice of life: Motor neurons relay signals from the nervous system to muscle fibers. In patients with spinal muscular atrophy, a protein required for the survival of these neurons is deficient or missing altogether, so the neurons gradually die and the patients' muscles waste away. The disease is currently untreatable. Naryshkin et al. discovered small-molecule drugs that cause cells to produce the missing protein by altering how a specific mRNA is put together, or “spliced” (see the Perspective by Vigevani and Valcárcel). When the researchers used the drugs to treat diseased mice, the mice showed marked improvement in muscle mass, motor function, and survival. Science , this issue p. 688 ; see also p. 624
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These screens, which are typically conducted in genetically engineered cell lines that harbour the target of interest, led to the discovery of the splice modulators risdiplam106 and branaplam107 for the treatment of spinal muscular atrophy”
From Human disease models in drug development (2023) · cites this paper as [106]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cited by
Items 201–300 of 533
Wu, Y., Chen, J., & Jong, Y. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01123-z · Cited by 33
Osman, E. Y., Washington, C. W., Kaifer, K. A., Mazzasette, C., Patitucci, T. N., Florea, K. M., Simon, M. E., Ko, C., Ebert, A. D., & Lorson, C. L. (2016) · Molecular Therapy · doi:10.1038/mt.2016.145 · Cited by 35
Self-citationGenetic approaches to the treatment of inherited neuromuscular diseases
Ravi, B., Antonellis, A., Sumner, C. J., & Lieberman, A. P. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz131 · Cited by 30
Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy
Butchbach, M. E. R., Lumpkin, C. J., Harris, A. W., Saieva, L., Edwards, J. D., Workman, E., Simard, L. R., Pellizzoni, L., & Burghes, A. H. M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.009 · Cited by 33
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Zhou, H., Hong, Y., Scoto, M., Thomson, A. K., Pead, E., MacGillivray, T., Hernandez‐Gerez, E., Catapano, F., Meng, J., Zhang, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153430 · Cited by 34
Methods to identify and optimize small molecules interacting with RNA (SMIRNAs)
Ursu, A., Vézina‐Dawod, S., & Disney, M. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.019 · Cited by 33
“The identification of RNAs as key pathological agents in many diseases and the serendipitous discovery that small molecules identified from phenotypic screens act on the RNA [1] or premRNA and the RNA/spliceosome interface [2,3] support the notion of targeting RNA for therapeutic benefit.”
BackgroundThe Protein‐Coding Human Genome: Annotating High‐Hanging Fruits
Hatje, K., Mühlhausen, S., Simm, D., & Kollmar, M. (2019) · BioEssays · doi:10.1002/bies.201900066 · Cited by 34
The Role of cis- and trans-Acting RNA Regulatory Elements in Leukemia
Elcheva, I. A., & Spiegelman, V. S. (2020) · Cancers · doi:10.3390/cancers12123854 · Cited by 34
Servais, L., Baranello, G., Scoto, M., Daron, A., & Oskoui, M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1904889 · Cited by 33
RNATACs: Multispecific small molecules targeting RNA by induced proximity
Song, Y., Cui, J., Zhu, J., Kim, B., Kuo, M.-L., & Potts, P. R. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.05.006 · Cited by 31
RNA-binding proteins direct myogenic cell fate decisions
Wheeler, J. R., Whitney, O. N., Vogler, T. O., Nguyen, E. D., Pawlikowski, B. T., Lester, E., Cutler, A. A., Elston, T. L., Betta, N. D., Parker, K. R., et al. (2022) · eLife · doi:10.7554/elife.75844 · Cited by 26
Morishita, E. C. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2134852 · Cited by 29
Collaboration for rare disease drug discovery research
Litterman, N. K., Rhee, M., Swinney, D. C., & Ekins, S. (2014) · F1000Research · doi:10.12688/f1000research.5564.1 · Cited by 31
Deciphering targeting rules of splicing modulator compounds: case of TG003
Sakuma, M., Iida, K., & Hagiwara, M. (2015) · BMC Molecular Biology · doi:10.1186/s12867-015-0044-6 · Cited by 29
Biliouris, K., Gaitonde, P., Yin, W., Norris, D. A., Wang, Y., Henry, S. P., Fey, R. A., Nestorov, I. A., Schmidt, S., Rogge, M. C., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12323 · Cited by 29
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 30
Drug treatment for spinal muscular atrophy type I
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006281.pub5 · Cited by 32
Principles and correction of 5’-splice site selection
Malard, F., Mackereth, C. D., & Campagne, S. (2022) · RNA Biology · doi:10.1080/15476286.2022.2100971 · Cited by 30
Lin, T.-L., Chen, T., Hsu, Y.-Y., Cheng, Y.-H., Juang, B.-T., & Jong, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154723 · Cited by 27
Small molecule targeting of RNA structures in neurological disorders
Angelbello, A. J., Chen, J. L., & Disney, M. D. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14051 · Cited by 28
Structural insights of the conserved “priming loop” of hepatitis B virus pre-genomic RNA
LeBlanc, R. M., Kasprzak, W. K., Longhini, A. P., Olenginski, L. T., Abulwerdi, F. A., Ginocchio, S., Shields, B., Nyman, J., Svirydava, M., Vecchio, C. D., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1934544 · Cited by 26
Feng, Z., Lam, S., Tenn, E.-M. S., Ghosh, A. S., Cantor, S., Zhang, W., Yen, P., Chen, K. S., Burden, S. J., Paushkin, S. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158015 · Cited by 28
“We have previously shown that SMN-modifiers and the FDA-approved Risdiplam improve NMJ innervation significantly, but even with the optimal treatments, NMJ deficits remain in some denervation-vulnerable muscles in the delta7 SMA mice [37,38].”
BackgroundSelf-citationRecent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Haque, U. S., & Yokota, T. (2024) · Genes · doi:10.3390/genes15080999 · Cited by 28
“This process identified a promising coumarin derivative [86].”
BackgroundDynamic interactions drive early spliceosome assembly
Martínez‐Lumbreras, S., Morguet, C., & Sattler, M. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102907 · Cited by 35
Stevens, M., & Oltean, S. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080908 · Cited by 29
Advances in modeling and treating spinal muscular atrophy
Alstyne, M. V., & Pellizzoni, L. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000368 · Cited by 26
Big win possible for Ionis/Biogen antisense drug in muscular atrophy
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1016-1002 · Cited by 26
Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice
Kray, K. M., McGovern, V. L., Chugh, D., Arnold, W. D., & Burghes, A. H. M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105488 · Cited by 26
Adult-onset spinal muscular atrophy: An update
Morales, R. J., Pageot, N., Taïeb, G., & Camu, W. (2017) · Revue Neurologique · doi:10.1016/j.neurol.2017.03.015 · Cited by 30
Swalley, S. E. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115239 · Cited by 24
Targeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40
Tong, Y., Childs‐Disney, J. L., & Disney, M. D. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17308 · Cited by 28
“A prominent example is the FDA-approved drug, risdiplam (Naryshkin et al., 2014), as a treatment for spinal muscular atrophy (SMA).”
Yanaizu, M., Sakai, K., Tosaki, Y., Kino, Y., & Satoh, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25204-2 · Cited by 24
Advances in machine-learning approaches to RNA-targeted drug design
Zhou, Y., & Chen, S. (2024) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2024.100053 · Cited by 26
The evolution and application of RNA-focused small molecule libraries
Taghavi, A., Springer, N. A., Zanon, P. R. A., Li, Y., Li, C., Childs‐Disney, J. L., & Disney, M. D. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00272e · Cited by 32
Borges, B., Brown, S. M., Chen, W., Clarke, M. T., Herzeg, A., Park, J. H., Ross, J., Kong, L., Denton, M., Smith, A. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv4656 · Cited by 24
Translational development of splice-modifying antisense oligomers
Fletcher, S., Bellgard, M., Price, L., Akkari, P. A., & Wilton, S. D. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1250880 · Cited by 28
Small-Molecule Screening for Genetic Diseases
Markossian, S., Ang, K. K. H., Wilson, C. G. M., & Arkin, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021452 · Cited by 26
Hensel, N., Cieri, F., Santonicola, P., Tapken, I., Schüning, T., Taiana, M. M., Pagliari, E., Joseph, A., Fischer, S., Heidrich, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007785118 · Cited by 23
Sigala, I., George, G., Thysiadis, S., Zografos, A. L., Giannakouŕos, T., Sarli, V., & Nikolakaki, E. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.01.025 · Cited by 23
Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy
Kirschner, J., & Pechmann, A. (2017) · Neuropediatrics · doi:10.1055/s-0037-1603517 · Cited by 31
Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige
Natua, S., Ashok, C., & Shukla, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03727-0 · Cited by 24
Otsuki, N., Arakawa, R., Kaneko, K., Aoki, R., Arakawa, M., & Saito, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201764 · Cited by 23
R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy
Tejero, R., Balk, S., Franco-Espín, J., Ojeda, J., Hennlein, L., Drexl, H., Dombert, B., Clausen, J.-D., Torres‐Benito, L., Saal-Bauernschubert, L., et al. (2020) · iScience · doi:10.1016/j.isci.2020.100826 · Cited by 26
Modern approaches in gene therapy of motor neuron diseases
Zakharova, M. N. (2020) · Medicinal Research Reviews · doi:10.1002/med.21705 · Cited by 25
Qiao, Y., Chi, Y., Gu, J., & Ma, Y. (2023) · Brain Sciences · doi:10.3390/brainsci13101419 · Cited by 29
Investigational therapies for the treatment of spinal muscular atrophy
Kaczmarek, A., Schneider, S. M., Wirth, B., & Rießland, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1038341 · Cited by 27
ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice
Abera, M. B., Xiao, J., Nofziger, J. H., Titus, S., Southall, N. T., Zheng, W., Moritz, K. E., Ferrer, M., Cherry, J. J., Androphy, E. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88427 · Cited by 24
Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA)
Lefebvre, S., & Sarret, C. (2020) · Archives de Pédiatrie · doi:10.1016/s0929-693x(20)30269-4 · Cited by 30
Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes
Singh, N. N., Howell, M. D., & Singh, R. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00005-7 · Cited by 24
Inborn errors of metabolism: Lessons from iPSC models
Escribá, R., Ferrer‐Lorente, R., & Raya, Á. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09671-z · Cited by 25
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
Errico, F., Marino, C., Grimaldi, M., Nuzzo, T., Bassareo, V., Valsecchi, V., Panicucci, C., Schiavi, E. D., Mazza, T., Bruno, C., et al. (2022) · Biomolecules · doi:10.3390/biom12101431 · Cited by 26
Silvestri, I., Manigrasso, J., Andreani, A., Brindani, N., Mas, C., Reiser, J., Vidossich, P., Martino, G., McCarthy, A. A., Vivo, M. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48697-0 · Cited by 24
Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing
Odermatt, P., TRUEB, J., Furrer, L., Fricker, R., Marti, A., & Schümperli, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.152 · Cited by 26
Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy
Lejman, J., Zieliński, G., Gawda, P., & Lejman, M. (2021) · Genes · doi:10.3390/genes12091346 · Cited by 25
Bergant, V., Schnepf, D., Krätzig, N. D. A., Hubel, P., Urban, C., Engleitner, T., Dijkman, R., Ryffel, B., Steiger, K., Knolle, P. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40469-6 · Cited by 23
GEMINs: potential therapeutic targets for spinal muscular atrophy?
Borg, R. M., & Cauchi, R. J. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00325 · Cited by 22
“In addition, proprietary molecules developed by PTC Therapeutics Inc. in partnership with Roche are able to correct alternative splicing of the SMN2 gene (Naryshkin et al., 2012, 2014).”
BackgroundSeranova, E., Palhegyi, A. M., Verma, S., Dimova, S., Lasry, R., Naama, M., Sun, C., Barrett, T. G., Rosenstock, T. R., Kumar, D., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.024 · Cited by 23
Wiesenfeldt, M. P., Moock, D., Paul, D., & Glorius, F. (2021) · Chemical Science · doi:10.1039/d0sc07099h · Cited by 20
Reprogramming RNA processing: an emerging therapeutic landscape
Neil, C. R., Seiler, M., Reynolds, D. J., Smith, J. J., Vaillancourt, F. H., Smith, P. G., & Agrawal, A. A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.011 · Cited by 23
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
Valsecchi, V., Errico, F., Bassareo, V., Marino, C., Nuzzo, T., Brancaccio, P., Laudati, G., Casamassa, A., Grimaldi, M., D’Amico, A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05543-1 · Cited by 24
Small molecules modulating RNA splicing: a review of targets and future perspectives
Bouton, L., Ecoutin, A., Malard, F., & Campagne, S. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00685a · Cited by 21
Proprioceptive synaptic dysfunction is a key feature in mice and humans with spinal muscular atrophy
Simon, C. M., Delestrée, N., Montes, J., Sowoidnich, L., Gerstner, F., Carranza, E., Buettner, J. M., Pagiazitis, J. G., Prat-Ortega, G., Ensel, S., et al. (2025) · Brain · doi:10.1093/brain/awaf074 · Cited by 22
Approaches for the Discovery of Small Molecule Ligands Targeting microRNAs
Lorenz, D. A., & Garner, A. L. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_3 · Cited by 23
SEC23A rescues SEC23B-deficient congenital dyserythropoietic anemia type II
King, R., Lin, Z., Balbin-Cuesta, G., Myers, G., Friedman, A. D., Zhu, G., McGee, B. M., Saunders, T. L., Kurita, R., Nakamura, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5293 · Cited by 24
Progress in spinal muscular atrophy research
Wurster, C. D., & Petri, S. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001102 · Cited by 18
“Risdiplam with its various analogs were identified in high-throughput studies with cell-based screening systems, in which a luciferase reporter protein was expressed only when exon 7 of the SMN2 gene was included after splicing [45].”
BackgroundAn Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Li, Y., Zeng, H., Wei, Y., Ma, X., & He, Z. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.189 · Cited by 20
Crisafulli, S., Boccanegra, B., Vitturi, G., Trifirò, G., & Luca, A. D. (2023) · Brain Sciences · doi:10.3390/brainsci13101446 · Cited by 25
Spinal muscular atrophy: Factors that modulate motor neurone vulnerability
Tu, W.-Y., Simpson, J. E., Highley, J. R., & Heath, P. R. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.01.011 · Cited by 21
“In general, this can be achieved by delivering synthetic DNA-like molecules to correct the splicing pattern [143-156], or small chemical compounds to alter the gene structure by inhibiting histone deacetylase [157-167].”
BackgroundCherry, J. J., DiDonato, C. J., Androphy, E. J., Calò, A., Potter, K., Custer, S. K., Du, S., Foley, T. L., Gopalsamy, A., Reedich, E. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185079 · Cited by 18
Therapeutic approaches to treat human spliceosomal diseases
DeNicola, A. B., & Tang, Y. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.003 · Cited by 17
Poison exons: tuning RNA splicing for targeted gene regulation
Neil, C. R., Schaening-Burgos, C., Alexis, M. S., Reynolds, D. J., Smith, P. G., Seiler, M., Vaillancourt, F. H., & Agrawal, A. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.01.002 · Cited by 20
Boti, M. A., Diamantopoulos, M. A., & Scorilas, A. (2025) · Genes · doi:10.3390/genes16101168 · Cited by 23
“Additionally, small molecules can modulate alternative splicing by stabilizing interactions between pre-mRNA and components of the spliceosome, such as U1 snRNP (Figure 4A) [187].”
A sequential binding mechanism for 5′ splice site recognition and modulation for the human U1 snRNP
White, D. S., Dunyak, B. M., Vaillancourt, F. H., & Hoskins, A. A. (2024) · Nature Communications · doi:10.1038/s41467-024-53124-5 · Cited by 23
Cicero, A. L., & Nissan, X. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.10.002 · Cited by 17
Campagne, S., de Vries, T., Malard, F., Afanasyev, P., Dorn, G., Dedic, E., Kohlbrecher, J., Boehringer, D., Cléry, A., & Allain, F. H. ‐. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab135 · Cited by 17
Axford, J., Sung, M. J., Manchester, J. I., Chin, D. N., Jain, M., Shin, Y., Dix, I., Hamann, L. G., Cheung, A. K., Sivasankaran, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02173 · Cited by 18
Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators
Chappie, T. A., Abdelmessih, M., Ambroise, C., Boehm, M., Cai, M., Green, M., Guilmette, E. R., Steppan, C. M., Stevens, L. M., Wei, L., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00396 · Cited by 19
Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
Wang, Y., Xu, C., Ma, L., Mou, Y., Zhang, B., Zhou, S., Tian, Y., Trinh, J., Zhang, X., & Li, X.-J. (2019) · Life Science Alliance · doi:10.26508/lsa.201800268 · Cited by 18
“In contrast, RG7800, which can down-regulate the proportion of SMN-Δ 7 splicing, signi fi cantly decreased GFP intensity in SMN2-GFP reporter cells (Fig S1).”
InfluentialSelf-citationVarderidou‐Minasian, S., Verheijen, B. M., Harschnitz, O., Kling, S., Karst, H., van der Pol, W. L., Pasterkamp, R. J., & Altelaar, M. A. F. (2021) · ACS Omega · doi:10.1021/acsomega.1c04688 · Cited by 15
Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders
Pagliarini, V., Rosa, P. L., & Sette, C. (2017) · Human Genetics · doi:10.1007/s00439-017-1802-y · Cited by 17
RNP Assembly Defects in Spinal Muscular Atrophy
Price, P. L., Morderer, D., & Rossoll, W. (2018) · Advances in neurobiology · doi:10.1007/978-3-319-89689-2_6 · Cited by 26
Novel Splice-Site Mutation in SMN1 Associated with a very Severe SMA-I Phenotype
Ronchi, D., Previtali, S. C., Sora, M. G. N., Barera, G., Menico, B. D., Corti, S. P., Bresolin, N., & Comi, G. P. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0483-4 · Cited by 17
“This finding confirms the major effects of a slight increase in SMN protein in patients with better clinical outcomes and supports this line of intervention for experimental therapies (Naryshkin et al. 2014).”
Studying human disease using human neurons
Ahfeldt, T., Litterman, N. K., & Rubin, L. L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.051 · Cited by 18
“In both the SMA and ALS models, significant differences between the human and animal form of the disease exist, including the mechanism of death and the high level of expression of the human protein required.”
BackgroundInfluentialSelf-citationRietz, A., Li, H., Quist, K. M., Cherry, J. J., Lorson, C. L., Burnett, B. G., Kern, N. L., Calder, A. N., Fritsche, M., Lusic, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01885 · Cited by 18
Reversible Control of RNA Splicing by Photoswitchable Small Molecules
Zhang, L., Xie, X., Djoković, N., Nikolić, K., Kosenkov, D., Abendroth, F., & Vázquez, O. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03275 · Cited by 15
Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA
Konieczny, P., & Artero, R. D. (2019) · The FASEB Journal · doi:10.1096/fj.201802554rrr · Cited by 15
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 19
Targeting RNA-protein interactions with small molecules: promise and therapeutic potential
Rhodes, C. A., Balaratnam, S., Yazdani, K., Seshadri, S., & Schneekloth, J. S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03342-9 · Cited by 17
Developing therapies for spinal muscular atrophy
Wertz, M. H., & Şahin, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12813 · Cited by 17
Quancard, J., Bach, A., Cox, B. J., Craft, R., Finsinger, D., Guéret, S. M., Hartung, I. V., Laufer, S., Messinger, J., Sbardella, G., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100041 · Cited by 15
Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases
Karpe, Y., Chen, Z.-Y., & Li, X.-J. (2021) · Pharmaceuticals · doi:10.3390/ph14060565 · Cited by 17
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
López‐Cortés, A., Echeverría‐Garcés, G., & Ramos-Medina, M. J. (2022) · Biology · doi:10.3390/biology11060894 · Cited by 17
Chiriboga, C. A. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00529-8 · Cited by 14
Bush, J. A., Williams, C. C., Meyer, S. M., Tong, Y., Haniff, H. S., Childs‐Disney, J. L., & Disney, M. D. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00014 · Cited by 14
Discovery of RNA‐Targeting Small Molecules: Challenges and Future Directions
Cai, Z., Ma, H., Ye, F., Lei, D., Deng, Z., Li, Y., Gu, R., & Wen, H. (2025) · MedComm · doi:10.1002/mco2.70342 · Cited by 20
“SMN-C3 was the first SMN2 splicing modifier identified by chemical screening and optimization (Figure 2B) [113].”
Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches
Tegtmeyer, M., & Nehme, R. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167221 · Cited by 13
Fullenkamp, C. R., Mehdi, S., Jones, C. P., Tenney, L., Pichling, P., Prestwood, P. R., Ferré-D’Amaré, A. R., Tiwary, P., & Schneekloth, J. S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505971 · Cited by 14
Harris, A. W., & Butchbach, M. E. R. (2015) · Neuromuscular Disorders · doi:10.1016/j.nmd.2015.05.008 · Cited by 13
“In addition to regulating its promoter, other approaches showing in vivo efficacy for increasing SMN2 expression include modulation of the splicing of its pre-mRNA so that a greater proportion of SMN2 mRNAs contain exon 7 with compounds like LDN-76070 [29] and SMN-C3 [30] and translational read-through of SMNΔ7 mRNAs…”
BackgroundSecurinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells
Chen, Y., Chang, J., Liu, T., Jong, Y., Cheng, W.-L., & Yuo, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.104 · Cited by 13
Metadata
- Authors
- Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., Ma, J., Turpoff, A., Lee, C.-S., Zhang, X., Moon, Y.-C., Trifillis, P., Welch, E. M., Colacino, J. M., Babiak, J., Almstead, N. G., Peltz, S. W., Eng, L. A., Chen, K. S., Mull, J. L., Lynes, M. S., Rubin, L. L., Fontoura, P., Santarelli, L., Haehnke, D., McCarthy, K. D., Schmucki, R., Ebeling, M., Sivaramakrishnan, M., Ko, C.-P., Paushkin, S. V., Ratni, H., Gerlach, I., Ghosh, A., & Metzger, F.
- Affiliations
- PTC Therapeutics (United States) (US)
- University of Southern California (US)
- Spinal Muscular Atrophy Foundation (US)
- Harvard University (US)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
- Corresponding author
- Peltz, Stuart W.
- Metzger, Friedrich
- ORCID
- Naryshkin, Nikolai A.
- Weetall, Marla
- Narasimhan, Jana
- Zhao, Xin
- Ling, Karen K. Y.
- Chen, Guangming
- Zhang, Nanjing
- Sheedy, Josephine
- Kong, Ronald
- Ma, Jiyuan
- Moon, Young-Choon
- Welch, Ellen M.
- Colacino, Joseph M.
- Peltz, Stuart W.
- Chen, Karen S.
- Rubin, Lee L.
- Fontoura, Paulo
- Ebeling, Martin
- Ko, Chien-Ping
- Paushkin, Sergey V.
- Ratni, Hasane
- Metzger, Friedrich
- Venue
- Science
- Published
- 2014-08-08
- Volume
- 345
- Issue
- 6197
- Pages
- 688-693
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992985034
- Cited by
- 524
- References
- 56
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 47 · 2023: 33 · 2022: 50 · 2021: 54 · 2020: 34 · 2019: 47 · 2018: 50 · 2017: 44 · 2016: 59 · 2015: 35 · 2014: 12
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- spinal muscular atrophy, SMN2, SMN1, alternative splicing, small molecules, SMN protein, motor function, lifespan extension, neuromuscular degeneration, compound screening
- MeSH terms
- Administration, Oral, Animals, Cells, Cultured, Coumarins, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Longevity, Muscular Atrophy, Spinal, Pyrimidinones, RNA, Messenger, Sequence Deletion, Alternative Splicing, Isocoumarins, Mice, Small Molecule Libraries, Survival of Motor Neuron 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.